BRCA1 and ovarian carcinoma: A pre-clinical study also showed that guadecitabine, a methyltransferase inhibitor, in combination with the PARPi talazoparib, inhibited breast and ovarian cancers harboring either wild-type- or mutant-BRCA1/2 [65].